NO20080046L - Fremgangsmater for administrering av vaksine, nye feline calicivirus, og behandlinger for a immunisere dyr mot feline paraovirus og feline herpesvirus - Google Patents

Fremgangsmater for administrering av vaksine, nye feline calicivirus, og behandlinger for a immunisere dyr mot feline paraovirus og feline herpesvirus

Info

Publication number
NO20080046L
NO20080046L NO20080046A NO20080046A NO20080046L NO 20080046 L NO20080046 L NO 20080046L NO 20080046 A NO20080046 A NO 20080046A NO 20080046 A NO20080046 A NO 20080046A NO 20080046 L NO20080046 L NO 20080046L
Authority
NO
Norway
Prior art keywords
vaccine
feline
nucleic acid
feline calicivirus
calicivirus
Prior art date
Application number
NO20080046A
Other languages
English (en)
Inventor
Cassius Mcallister Tucker
David Earl Lowery
Sing Rong
Paul Mark Guimond
Paula Munns Clare
Thomas Jack Newby
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20080046L publication Critical patent/NO20080046L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)

Abstract

Det beskrives en vaksine for å immunisere en katt mot feline virus. Det beskrives også nukleinsyrekloner som koder for capsidproteinet av isolert felin calicivirus. Foreliggende oppfinnelse vedrører ytterligere en levende eller drept vaksine omfattende isolerte feline calicivirus, en subenhetvaksine omfattende capsidproteinet av det isolerte feline calicivirus, en nukleinsyrevaksine omfattende en nukleinsyreklon av det isolerte feline calicivirus, og en rekombinant virusvektorvaksine omfattende nukleinsyrer som koder for capsidproteinet av det isolerte feline calicivirus. Foreliggende oppfinnelse vedrører også en fremgangsmåte for å identifisere et felint calicivirus som er nyttig for å produsere en vaksinesammensetning og for å analysere for og å diagnostisere katter infisert med feline calicivirus. Også beskrevet er en fremgangsmåte for å immunisere dyr, spesielt katter, mot sykdom, fortrinnsvis mot feline calicivirus (KV). Fremgangsmåten inkluderer å administrere til en katt terapeutisk effektive mengder av første og andre FCV-vaksiner. Den første vaksine administreres oralt eller parenteralt (for eksempel subkutanøst, intramuskulært og lignende). Den andre vaksine administreres oralt eller oronasalt N dager etter administrering av den første vaksine, hvor N er et heltall fra 3 til 120, inkluderende. En tredje vaksine administrering kan også gis. Foreliggende oppfinnelse beskriver også fremgangsmåter og materialer for å behandle og immunisere dyr med vaksiner, og spesielt katter mot både FPV eller feline parvovirus, som også har blitt benevnt panleukopenia eller FPL, og mot en ytterligere sykdom, FHV eller felin herpesvirus, som også har blitt benevnt felin rinotrakeitis virus.
NO20080046A 2005-07-28 2008-01-03 Fremgangsmater for administrering av vaksine, nye feline calicivirus, og behandlinger for a immunisere dyr mot feline paraovirus og feline herpesvirus NO20080046L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70310905P 2005-07-28 2005-07-28
PCT/IB2006/002018 WO2007012944A2 (en) 2005-07-28 2006-07-17 Methods of vaccine administration, new feline caliciviruses, and treatments for immunizing animals against feline paraovirus and feline herpes virus

Publications (1)

Publication Number Publication Date
NO20080046L true NO20080046L (no) 2008-01-30

Family

ID=37198861

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20080046A NO20080046L (no) 2005-07-28 2008-01-03 Fremgangsmater for administrering av vaksine, nye feline calicivirus, og behandlinger for a immunisere dyr mot feline paraovirus og feline herpesvirus

Country Status (18)

Country Link
US (2) US7790169B2 (no)
EP (2) EP2292250A1 (no)
JP (3) JP5318573B2 (no)
KR (1) KR20080025197A (no)
CN (4) CN104758927B (no)
AR (1) AR057695A1 (no)
AT (1) ATE496629T1 (no)
AU (2) AU2006273753B2 (no)
BR (1) BRPI0614119B8 (no)
CA (1) CA2617341C (no)
DE (1) DE602006019878D1 (no)
ES (1) ES2357679T3 (no)
HK (2) HK1194303A1 (no)
MX (1) MX2008001326A (no)
NO (1) NO20080046L (no)
RU (1) RU2008102930A (no)
TW (1) TW200740454A (no)
WO (1) WO2007012944A2 (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2617341C (en) * 2005-07-28 2011-03-29 Pfizer Products Inc. Methods of vaccine administration, new feline caliciviruses, and treatments for immunizing animals against feline paraovirus and feline herpes virus
JP6200155B2 (ja) * 2010-03-05 2017-09-20 インターベット インターナショナル ベー． フェー． 組換え弱毒化パルボウイルス
JP2012044910A (ja) * 2010-08-25 2012-03-08 Chubu Food & Environmental Safety Center Co Ltd ネコカリシウイルス遺伝子の発現用ベクター及びこれを用いたウイルスの製造方法
WO2012030720A1 (en) * 2010-08-31 2012-03-08 Merial Limited Newcastle disease virus vectored herpesvirus vaccines
WO2013026054A2 (en) * 2011-08-18 2013-02-21 Axella Solutions, Llc Production of infectious rna viruses in yeast
CN103773739B (zh) * 2013-03-01 2016-06-15 上海启盛生物科技有限公司 一种猫泛白细胞减少症病毒减毒疫苗株及其应用
CN103276106B (zh) * 2013-05-03 2014-09-03 中国农业科学院哈尔滨兽医研究所 用于同时检测猫泛白细胞减少症病毒、猫杯状病毒和猫疱疹病毒1型的多重pcr引物组
EP3256219B1 (en) 2015-02-10 2021-11-17 Ohio State Innovation Foundation Chlamydia-activated b cell platforms and methods thereof
MX2018002112A (es) * 2015-08-20 2019-03-28 Merial Inc Vacunas recombinantes contra el calicivirus felino (fcv) y sus usos.
WO2017083337A1 (en) * 2015-11-10 2017-05-18 Ohio State Innovation Foundation Methods and compositions related to accelerated humoral affinity
EP4141022A1 (en) * 2015-12-23 2023-03-01 Intervet International B.V. Feline calicivirus vaccine
CN106190988B (zh) * 2016-07-13 2020-01-07 长春西诺生物科技有限公司 猫嵌杯病毒ch-jl5株灭活疫苗
CN108362877A (zh) * 2018-01-24 2018-08-03 中国农业科学院兰州畜牧与兽药研究所 猫杯状病毒荧光免疫层析检测试纸条及其制备方法
CN108371710B (zh) * 2018-01-30 2021-09-21 长春西诺生物科技有限公司 猫传染性鼻结膜炎和猫泛白细胞减少症二联疫苗及制备方法
CN112921122A (zh) * 2021-03-26 2021-06-08 广西大学 猫常见病毒多重pcr快速检测试剂盒及其引物组
CN113943354B (zh) * 2021-10-11 2022-09-06 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) 一种重组猫疱疹病毒gB蛋白抗原及其在抗体诊断和疫苗制备中的应用
CN113943830A (zh) * 2021-10-14 2022-01-18 广州悦洋生物技术有限公司 一种用于同时检测猫细小病毒、猫疱疹病毒1型和猫杯状病毒的引物探针组及试剂盒
CN114634564B (zh) * 2022-04-18 2023-04-04 北京华驰千盛生物科技有限公司 猫用三联卵黄抗体、制剂及制备方法与用途
CN114874997B (zh) * 2022-05-26 2023-05-23 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） 猫杯状病毒
CN115058541B (zh) * 2022-06-17 2023-05-09 湖南大圣宠医生物科技有限公司 检测猫口炎病原体并分型的组合物、试剂盒、方法及其用途
CN115969967B (zh) * 2023-01-10 2023-08-04 浙江大学 用于预防猫鼻气管炎、猫杯状病毒病、猫泛白细胞减少症的三联mRNA疫苗及其制备方法
CN117143924B (zh) * 2023-09-11 2024-03-22 华中农业大学 共表达猫杯状病毒和猫细小病毒抗原蛋白的重组猫疱疹病毒及其活载体疫苗和应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3937817A (en) * 1973-02-28 1976-02-10 Bayer Aktiengesellschaft Pharmaceutical compositions containing a saccharase inhibitor
US3937312A (en) 1974-10-04 1976-02-10 The Torrington Company Retainer for roller clutch
US3944469A (en) 1974-11-21 1976-03-16 Pitman-Moore, Inc. Feline calicivirus vaccine and production thereof
US3937812A (en) 1974-11-21 1976-02-10 Pitman-Moore, Inc. Feline calicivirus vaccine and production thereof
US4486530A (en) 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4522810A (en) * 1982-12-09 1985-06-11 The Regents Of The University Of California Feline calicivirus vaccine
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
EP0231039B1 (en) 1986-01-14 1992-01-08 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Process for preparing immunological complexes and pharmaceutical composition containing these complexes
US4786589A (en) 1986-08-18 1988-11-22 Huntington Medical Research Institute Immunoassay utilizing formazan-prelabeled reactants
US5169789A (en) 1986-12-03 1992-12-08 New Horizons Diagnostics Corporation Device and method for self contained solid phase immunodiffusion assay
US5266313A (en) 1987-02-03 1993-11-30 The United States Of America As Represented By The Department Of Health And Human Services Raccoon poxvirus as a gene expression and vaccine vector for genes of rabies virus and other organisms
JP2511494B2 (ja) 1988-05-12 1996-06-26 善治 松浦 日本脳炎ウイルス表面抗原蛋白質の製造法
US5620845A (en) 1988-06-06 1997-04-15 Ampcor, Inc. Immunoassay diagnostic kit
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5718901A (en) 1989-07-21 1998-02-17 Pharmacia & Upjohn Company Feline calicivirus gene
EP0484382B1 (en) 1989-07-21 1995-03-08 The Upjohn Company Feline calicivirus capsid protein and nucleotide sequence
US5226313A (en) * 1989-12-15 1993-07-13 Murata Mfg. Co., Ltd. Body fluid excretion measurement apparatus for medical application
US5252496A (en) 1989-12-18 1993-10-12 Princeton Biomeditech Corporation Carbon black immunochemical label
KR910014706A (ko) 1990-01-10 1991-08-31 원본미기재 세척이 필요없는 개량된 이뮤노어세이(immunoassay)장치
US5242686A (en) * 1990-11-07 1993-09-07 American Home Products Corporation Feline vaccine compositions and method for preventing chlamydia infections or diseases using the same
EP0575491B1 (en) 1991-03-07 2003-08-13 Virogenetics Corporation Genetically engineered vaccine strain
GB9112553D0 (en) 1991-06-11 1991-07-31 Wellcome Found Fusion proteins
US6241989B1 (en) * 1991-07-09 2001-06-05 Cornell Research Foundation, Inc. Recombinant multivalent viral vaccine
US5725863A (en) 1991-09-06 1998-03-10 The United States Of America As Represented By The Secretary Of Agriculture Polypeptides useful in prevention of chlamydia infection
ES2204900T3 (es) 1992-02-11 2004-05-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Estructura inmuinogena de doble vector.
US6010703A (en) 1993-07-26 2000-01-04 Board Of Trustees Operating Michigan State University Recombinant poxvirus vaccine against feline rhinotracheitis
US5695928A (en) 1993-12-10 1997-12-09 Novartis Corporation Rapid immunoassay for detection of antibodies or antigens incorporating simultaneous sample extraction and immunogenic reaction
US5561064A (en) 1994-02-01 1996-10-01 Vical Incorporated Production of pharmaceutical-grade plasmid DNA
US5800821A (en) 1995-03-10 1998-09-01 New England Medical Center Hospitals, Inc. Bacterial spores as a heat stable vaccine delivery system
EP2258726A1 (en) 1995-06-14 2010-12-08 The Regents of the University of California High affinity human antibodies to c-erbB-2
US5716784A (en) 1996-02-05 1998-02-10 The Perkin-Elmer Corporation Fluorescence detection assay for homogeneous PCR hybridization systems
US6231863B1 (en) * 1997-06-10 2001-05-15 American Cyanamid Company DNA sequences, molecules, vectors and vaccines for feline calicivirus disease and methods for producing and using same
WO2000076538A1 (en) 1999-06-10 2000-12-21 Michigan State University Feline calicivirus isolated from cat urine and vaccines thereof
FR2796282B1 (fr) * 1999-07-16 2001-10-26 Merial Sas Vaccin inactive contre la calicivirose feline
FR2796397B1 (fr) * 1999-07-16 2006-09-01 Merial Sas Genes de calicivirus felin et vaccins notamment vaccins recombines
US6534066B1 (en) * 1999-07-16 2003-03-18 Merial Inactivated vaccine against feline calicivirosis
WO2004083390A2 (en) 2003-03-14 2004-09-30 Regents Of The University Of California Virulent systemic feline calicivirus
WO2005080416A1 (en) * 2004-01-20 2005-09-01 Pharmacia & Upjohn Company Llc Feline calicivirus vaccines
CA2617341C (en) * 2005-07-28 2011-03-29 Pfizer Products Inc. Methods of vaccine administration, new feline caliciviruses, and treatments for immunizing animals against feline paraovirus and feline herpes virus

Also Published As

Publication number Publication date
JP5859923B2 (ja) 2016-02-16
CN101563096A (zh) 2009-10-21
BRPI0614119B1 (pt) 2016-10-11
JP2009502900A (ja) 2009-01-29
CA2617341A1 (en) 2007-02-01
HK1211864A1 (en) 2016-06-03
RU2008102930A (ru) 2009-07-27
DE602006019878D1 (de) 2011-03-10
US20070031454A1 (en) 2007-02-08
EP1912665B1 (en) 2011-01-26
CN103550768B (zh) 2016-01-20
HK1194303A1 (zh) 2014-10-17
TW200740454A (en) 2007-11-01
US8444997B2 (en) 2013-05-21
AU2006273753B2 (en) 2010-06-24
BRPI0614119B8 (pt) 2017-04-11
CN103550768A (zh) 2014-02-05
ATE496629T1 (de) 2011-02-15
CN104758927A (zh) 2015-07-08
ES2357679T3 (es) 2011-04-28
MX2008001326A (es) 2008-03-19
WO2007012944A3 (en) 2007-04-26
AU2006273753A2 (en) 2008-04-03
JP2013224295A (ja) 2013-10-31
CN103550767A (zh) 2014-02-05
WO2007012944A9 (en) 2008-10-16
US7790169B2 (en) 2010-09-07
JP5318573B2 (ja) 2013-10-16
EP1912665A2 (en) 2008-04-23
BRPI0614119A2 (pt) 2011-03-09
AU2010212382A1 (en) 2010-09-09
JP2012211161A (ja) 2012-11-01
AU2010212382B2 (en) 2013-06-06
WO2007012944A2 (en) 2007-02-01
CN104758927B (zh) 2017-11-21
AR057695A1 (es) 2007-12-12
CA2617341C (en) 2011-03-29
JP5847116B2 (ja) 2016-01-20
EP2292250A1 (en) 2011-03-09
CN103550767B (zh) 2017-04-19
KR20080025197A (ko) 2008-03-19
AU2006273753A1 (en) 2007-02-01
US20110052619A1 (en) 2011-03-03

Similar Documents

Publication Publication Date Title
NO20080046L (no) Fremgangsmater for administrering av vaksine, nye feline calicivirus, og behandlinger for a immunisere dyr mot feline paraovirus og feline herpesvirus
ES2625460T5 (es) Tratamiento de cerdos seropositivos en anticuerpo anti-PCV2 con antígeno de PCV2
AU2020277165B2 (en) Feline calicivirus vaccine
JP2018535251A (ja) ブタサーコウイルス３型免疫原性組成物、その製造方法、およびその使用方法
EA200301323A1 (ru) Однократная вакцинация mycoplasma hyopneumoniae
EP3432922B1 (en) Orf virus-based platform for vaccine delivery
PH12019500592A1 (en) New swine influenza vaccine
AR047581A1 (es) Vacunas de calicivirus felino
Moreno et al. Recombinant Rift Valley fever viruses encoding bluetongue virus (BTV) antigens: Immunity and efficacy studies upon a BTV-4 challenge
PT1734992E (pt) Vacinas melhoradas de fcv inactivado
JP7206383B2 (ja) 異種スパイクタンパク質を有する４／９１ ｉｂｖワクチン
CN106924726B (zh) 一种用于预防猪繁殖与呼吸综合征的疫苗组合物及其制备方法和应用
KR101937792B1 (ko) 신규한 재조합 항원 단백질을 포함하는 구제역 백신 조성물
EA200200743A1 (ru) Рекомбинантное ослабление вируса репродуктивного и респираторного синдрома свиней (prrsv)
JP2023528984A (ja) コロナウイルス病に対する組換え修飾ワクシニアウイルスアンカラ（ｍｖａ）ワクチン
US20130177582A1 (en) Parapoxvirus expressing the vp60 major capsid protein of the rabbit haemorrhagic disease virus
JP5946453B2 (ja) 変異狂犬病ウイルス及びワクチン
CA2439872A1 (en) Leporipox-based vector vaccines
RU2020122007A (ru) Поливалентная вакцина для животных семейства кошачьих
JP6132420B2 (ja) 変異狂犬病ウイルス合成・増殖方法、並びに狂犬病ワクチン製剤
WO2024079285A9 (en) Treatment using a one-to-stop attenuated sars-cov-2 virus
DE102005028271B4 (de) Proteingemisch enthaltend VSV-G zur Verstärkung der Immunantwort
JP2008534598A (ja) 免疫原の干渉を克服するための、慣習的なワクチンと組み合わせたｄｎａワクチンの使用
UY26563A1 (es) Atenuación recombinante de prrsv

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application